biOasis Enters Investor Relations Agreement with Gale Capital Corporation

biOasis Technologies Inc. (TSX VENTURE:BTI) (OTCQX:BIOAF) (the "Company") is
pleased to announce that is has retained Gale Capital Corporation ("Gale
Capital") effective June 15, 2014 to assist the Company with its shareholder
relations activities and investor awareness program.


Gale Capital will help by cultivating productive dialogue with analysts,
brokers, potential investors and current shareholders for the purpose of
expanding the Company's exposure within the Canadian and American investment
community. Gale Capital will also assist in the development and implementation
of an investor relations and communications program for purposes of attracting
prospective investors to the Company and strengthening the Company's profile
within the investment community.


"We are very pleased to be engaging Gale Capital and are very impressed with
their overall approach and strategy as discussed with the Company" said Rob
Hutchison, Chief Executive Officer of biOasis Technologies Inc. "In addition
internally we have hired a new member of the biOasis team, Ms. Tiffany Tolmie,
whom along with a number of corporate responsibilities will act as our corporate
communications liaison to our shareholders, a role that will go a great way to
increase external communications and support the efforts of the Gale group".


The initial term of this investor relations agreement is until June 15, 2015,
which the parties may extend by mutual consent, and either party may terminate
the agreement after September 15, 2014 with 30 days written notice. The Company
will pay a monthly fee in advance of CAD $6,000. Gale Capital will be granted
200,000 incentive share purchase options expiring on June 15, 2016 exercisable
at $1.23. The stock options will vest over 12 months, with 50,000 options
vesting on September 15, 2014, 50,000 on December 15, 2014, 50,000 on March 15,
2015 and 50,000 on June 15, 2015. The options follow the guidelines as set out
in Company's stock option plan and as set by TSX Venture Policy. The agreement
and options grant and terms are subject to the approval of the TSX Venture
Exchange.


About Gale Capital

Gale capital has provided quality investor relations services to publicly traded
companies globally since 1993. Their team of experienced professionals, key
affiliates and media personnel design and execute custom corporate
communications programs to meet individual company and shareholder requirements


About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis' proprietary brain delivery
platform, the company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
disorders such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the OTCQX under the symbol BIOAF and on the TSX Venture


Exchange under the symbol "BTI". For more information about the company please
visit www.bioasis.ca.


Herceptin(R) is a registered trademark of Genentech/Roche.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words


"believe", "may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Such forward-looking statements or
information involve known and unknown risks, uncertainties and other factors
that may cause our actual results, events or developments, or industry results,
to be materially different from any future results, events or developments
express or implied by such forward-looking statements or information. Such
factors include, among others, our stage of development, lack of any product
revenues, additional capital requirements, risk associated with the completion
of clinical trials and obtaining regulatory approval to market our products, the
ability to protect our intellectual property, dependence on collaborative
partners and the prospects for negotiating additional corporate collaborations
or licensing arrangements and their timing. Specifically, certain risks and
uncertainties that could cause such actual events or results expressed or
implied by such forward -looking statements and information to differ materially
from any future events or results expressed or implied by such statements and
information include, but are not limited to, the risks and uncertainties that:
products we develop may not succeed in preclinical or clinical trials, or future
products in our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise additional
capital; we may not be successful in establishing additional corporate
collaborations or licensing arrangements; we may not be able to establish
marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors 

Rob Hutchison Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release"


FOR FURTHER INFORMATION PLEASE CONTACT: 
Company Contact:
Rob Hutchison, Chairman & CEO
biOasis Technologies Inc.
778-383-3280
info@bioasis.ca


Tiffany Tolmie, Corporate Communications Liaison
biOasis Technologies Inc.
778 383 3280
Tiffany@bioasis.ca


Investor Relations Contact:
Gale Capital Corporation
604-200-1480
info@galecpital.com
BiOasis Technologies (TSXV:BTI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024